References
Elshof LE, Schmidt MK, Rutgers EJ, van Leeuwen FE, Wesseling J, Schaapveld M. Cause-specific mortality in a population-based cohort of 9799 women treated for ductal carcinoma in situ. Ann Surg. 2018;267(5):952–8.
Wiechmann L, Kuerer HM. The molecular journey from ductal carcinoma in situ to invasive breast cancer. Cancer. 2008;112(10):2130–42.
Sue GR, Lannin DR, Killelea B, Tsangaris T, Chagpar AB. Does time to definitive treatment matter in patients with ductal carcinoma in situ? Am Surg. 2013;79(6):561–5.
Bleicher RJ, Ruth K, Sigurdson ER, et al. Time to surgery and breast cancer survival in the United States. JAMA Oncol. 2016;2(3):330–9.
Ward WH, DeMora L, Handorf E, et al. Preoperative delays in the treatment of DCIS and the associated incidence of invasive breast cancer. Ann Surg Oncol. 2019. https://doi.org/10.1245/s10434-019-07844-4
Grimm LJ, Ryser MD, Partridge AH, et al. Surgical upstaging rates for vacuum assisted biopsy proven DCIS: implications for active surveillance trials. Ann Surg Oncol. 2017;24(12):3534–40.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
The authors report no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
ASO Author Reflections is a brief invited commentary on the article, “Preoperative Delays in the Treatment of DCIS and the Associated Incidence of Invasive Breast Cancer,” Ann Surg Oncol. 2019. https://doi.org/10.1245/s10434-019-07844-4.
Rights and permissions
About this article
Cite this article
Ward, W.H., Bleicher, R.J. ASO Author Reflections: Delays in the Treatment of DCIS—What are the Costs?. Ann Surg Oncol 27, 397–398 (2020). https://doi.org/10.1245/s10434-019-08062-8
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-019-08062-8